Jennifer Abraczinskas, MD
Family Medicine · Philadelphia, PANPI 1770921033
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.8% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Novo Nordisk at 43.4% of the total. That places this record below the midpoint for family medicine clinicians in PA, where the typical reported total is $257.
Across 25 payments — averaging $11.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$128
- Merck$28
- Amgen$25
- AstraZeneca$25
- Gilead$18
- Promius Pharma LLC$15
- plus $55 from 4 others
What the payments were for
- Speaking & faculty fees$155%
- Food & beverage$27192%
- Education$93%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 13 | $128 |
| Merck | 2 | $28 |
| Amgen | 2 | $25 |
| AstraZeneca | 2 | $25 |
| Gilead | 1 | $18 |
| Promius Pharma LLC | 1 | $15 |
| Acorda Therapeutics, Inc | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
| AbbVie | 1 | $14 |
| Lilly USA, LLC | 1 | $12 |
How this compares
$296 in reported general payments places this provider in the 50th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Paroxetine Hcl | 12 | $254 |
| Baclofen | 12 | $200 |
| Levothyroxine Sodium | 17 | $130 |
| Pantoprazole Sodium | 12 | $127 |
| Montelukast Sodium | 13 | $39 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Philadelphia
- Deborah WittPhiladelphia$226K
- Michael AttanasioPhiladelphia$214K
- Jonah MinkPhiladelphia$145K
- Celia EzidiegwuPhiladelphia$118K
- Glenn RosenPhiladelphia$61K
- Jessica DefflerPhiladelphia$56K
- Casey LaffertyPhiladelphia$55K
- Margot SavoyPhiladelphia$31K
- Neil SkolnikJenkintown$904K
- Lisa EspinozaNew Hope$722K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.